Inhalerx Ltd (IRX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.044x

Based on the latest financial reports, Inhalerx Ltd (IRX) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$38.91K ≈ $27.53K USD) by net assets (AU$-877.11K ≈ $-620.61K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Inhalerx Ltd (IRX) market capitalisation for the company's overall valuation and market capitalisation.

Inhalerx Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Inhalerx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Inhalerx Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Inhalerx Ltd ranked by their cash flow conversion efficiency. See IRX debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Decent Holding Inc Ordinary Shares NASDAQ:DXST	-0.411x
Anagenics Ltd AU:AN1	-0.099x
Henderson International Income Trust PLC LSE:HINT	0.024x
Capitan Investment Ltd V:CAI	0.042x
ASIA Capital Group Public Company Limited BK:ACAP	0.032x
Sultan Resources Ltd AU:SLZ	-0.130x
ScandiDos AB ST:SDOS	-0.020x
Sulliden Minerals SA TO:SMC	0.090x

Annual Cash Flow Conversion Efficiency for Inhalerx Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. View current stock price of Inhalerx Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$-63.97K ≈ $-45.26K	AU$-368.77K ≈ $-260.93K	5.765x	+295.55%
2023-12-31	AU$665.47K ≈ $470.86K	AU$-1.96 Million ≈ $-1.39 Million	-2.948x	-203.82%
2022-12-31	AU$1.90 Million ≈ $1.35 Million	AU$-1.85 Million ≈ $-1.31 Million	-0.970x	-126.23%
2021-12-31	AU$2.68 Million ≈ $1.89 Million	AU$-1.15 Million ≈ $-812.69K	-0.429x	+47.70%
2020-12-31	AU$1.32 Million ≈ $936.76K	AU$-1.09 Million ≈ $-768.25K	-0.820x	+85.05%
2019-12-31	AU$340.08K ≈ $240.63K	AU$-1.87 Million ≈ $-1.32 Million	-5.487x	-613.06%
2018-12-31	AU$2.68 Million ≈ $1.90 Million	AU$-2.06 Million ≈ $-1.46 Million	-0.770x	-35.45%
2017-12-31	AU$4.51 Million ≈ $3.19 Million	AU$-2.56 Million ≈ $-1.81 Million	-0.568x	-1717.88%
2016-12-31	AU$7.33 Million ≈ $5.19 Million	AU$-229.03K ≈ $-162.05K	-0.031x	--

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#29021 Global

#1593 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.39